Shares of HUTCHMED (China) Limited (NASDAQ:HCM – Get Rating) have been given a consensus recommendation of “Hold” by the six analysts that are covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $47.67.
Several equities analysts have commented on HCM shares. Zacks Investment Research cut HUTCHMED from a “buy” rating to a “hold” rating in a report on Thursday, May 5th. StockNews.com started coverage on HUTCHMED in a report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Deutsche Bank Aktiengesellschaft cut HUTCHMED from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th.
Several institutional investors and hedge funds have recently modified their holdings of HCM. General Atlantic L.P. acquired a new stake in HUTCHMED during the 3rd quarter valued at $146,440,000. Schroder Investment Management Group increased its holdings in HUTCHMED by 175.5% during the 3rd quarter. Schroder Investment Management Group now owns 3,030,051 shares of the company’s stock valued at $22,186,000 after purchasing an additional 1,930,312 shares in the last quarter. Bellevue Group AG increased its holdings in HUTCHMED by 62.6% during the 1st quarter. Bellevue Group AG now owns 1,750,690 shares of the company’s stock valued at $33,123,000 after purchasing an additional 673,820 shares in the last quarter. BlackRock Inc. increased its holdings in HUTCHMED by 14.9% during the 3rd quarter. BlackRock Inc. now owns 3,462,775 shares of the company’s stock valued at $126,771,000 after purchasing an additional 448,350 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in HUTCHMED by 185.0% during the 3rd quarter. Goldman Sachs Group Inc. now owns 610,058 shares of the company’s stock valued at $22,334,000 after purchasing an additional 396,026 shares in the last quarter. 31.03% of the stock is owned by institutional investors and hedge funds.
HUTCHMED stock opened at $9.56 on Friday. The business has a 50 day moving average price of $14.83 and a two-hundred day moving average price of $24.11. HUTCHMED has a 12 month low of $8.40 and a 12 month high of $43.94.
About HUTCHMED (Get Rating)
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider HUTCHMED, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and HUTCHMED wasn’t on the list.
While HUTCHMED currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.